Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: Evaluation of a prognostic score for survival after high-dose chemotherapy
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference16 articles.
1. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study—The German Testicular Cancer Cooperative Study Group;Siegert;J Clin Oncol,1994
2. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor;Loehrer;J Clin Oncol,1998
3. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer;Rick;J Clin Oncol,2001
4. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors;Kondagunta;J Clin Oncol,2005
5. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the german testicular cancer study group;Lorch;J Clin Oncol,2007
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Serum tumour markers in germ cell tumours: From diagnosis to cure;Critical Reviews in Oncology/Hematology;2021-03
2. État des lieux de la chimiothérapie intensive avec support de cellules-souches hématopoïétiques dans le traitement des tumeurs germinales;Bulletin du Cancer;2020-06
3. Response to first-line treatment and histology are associated with achieving complete remission after the first salvage high-dose chemotherapy in relapsing germ cell tumor patients;Bone Marrow Transplantation;2018-01-24
4. How Should Patients with Recurrent Disease Be Treated Actually?;Diagnosis and Management of Testicular Cancer;2015
5. Salvage therapy for refractory or recurrent pediatric germ cell tumors: The french SFCE experience;Pediatric Blood & Cancer;2013-08-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3